期刊文献+

2种单硬脂酸甘油酯固体脂质纳米粒制剂的体内组织分布及药动学研究 被引量:3

In Vivo Tissues Distribution and Pharmacokinetics:Survey of2Kinds of Monostearin Solid Lipid Nanoparticle Preparations
暂未订购
导出
摘要 目的:研究单硬脂酸甘油酯固体脂质纳米粒(MSLN)和经聚乙二醇2000(PEG2000)修饰后的MSLN(PEG-MSLN)在小鼠体内的组织分布及其在大鼠体内的药动学,考察PEG2000修饰对MSLN体内组织分布及药动学的影响。方法:采用溶剂扩散法制备MSLN,测定其粒径和Zeta电位;以罗丹明B为荧光标记物,测定和计算2种MSLN制剂经鼠尾静脉注射后的体内组织分布及药动学参数。结果:2种MSLN制剂粒径分布相似,Zeta电位约为—20mV;经鼠尾静脉注射后,MSLN靶向肝脏,且经PEG2000修饰后的纳米粒体循环时间可显著延长至2·2倍。结论:MSLN经PEG2000修饰后可改善体循环,其可作为肝脏靶向的药物载体。 OBJECTIVE: To investigate the tissues distribution of monostearin solid lipid nanoparticles(MSLN)and MSLN (PEG MSLN) that had been modified by PEG2000 in vivo of mice and the pharmacokinetics in vivo of rats, and to investigate the influence of PEG2000 modification on MSLN tissues distribution and pharmacokinetics. METHODS; MSLN was prepared by a novel solvent diffusion method. The particle diameters and Zeta potentials of MSLN were determined. Tissues distributions and pharmacokinetics of 2 kinds of MSLN preparations in vivo of rats after vena caudalis administration were determined and the determining results were calculated with rhodamine B as fluorescent marker. RESULTS:2 kinds of MSLN preparations showed a similar particle diameter distribution with Zeta potential of MSLN at -20mV. MSLN targeted to liver after vena caudalis intravenous injection and the general circulation of nanoparticles was significantly prolonged to 2.2 times after modified by PEG2000. CONCLUSION : MSLN can amelioration systemic circulation after modification with PEG 2000 and which can be used as liver targeted drug carrier.
出处 《中国药房》 CAS CSCD 北大核心 2006年第4期253-255,共3页 China Pharmacy
关键词 单硬脂酸甘油酯 固体脂质纳米粒 聚乙二醇2000 组织分布 药动学 Monostearin Solid lipid nanoparticles PEG2000 Tissue distribution Pharmacokinetics
  • 相关文献

参考文献6

  • 1Muller RH, Mader K, Gohla S. Solid lipid nanoparticles(SLN) for controlled drug delivery-a review of the state of the art [J]. Eur J Pharm Biopharm , 2000,50 (1):161.
  • 2Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnctic magnetite nanoparticles and their intracellular uptake [J] . Biomaterials , 2002, 23(7).1 553.
  • 3Gessner A,Waicz R, Lieske A,et al. Nanoparticles with deereasing surface hydrophobieities influence on plasma protein adsorption [J] . Int J Pharm , 2000, 196(2):245.
  • 4Claudia B, Roberta C, Ludovica G, et al. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles [J] . Int J Pharm , 1998, 175(2) :185.
  • 5Alessandro B, Roberta C, Gian PZ, et al .Transmucosal transport of tobramycin incorporated in solid lipid nanopartieles(SLN) after duodenal administration to rats.Part Ⅱ tissue distribution [J] .Pharmacological Research , 2001,43(5) ;497.
  • 6Gian PZ, Roberta C, Anna F, et al. Pharmacokinet ics of doxorubicin incorporated in solid lipid nanoparticles (SLN) [J ]. Pharmacological Research, 1999,40(3) :281.

同被引文献33

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部